A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
about
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionConsensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.Back to the future: recombinant polyclonal antibody therapeutics.Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.Potential vaccines and post-exposure treatments for filovirus infections.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignRespiratory syncytial virus: current progress in vaccine development.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Novel therapies and vaccines against the human respiratory syncytial virus.New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.Adherence and outcomes: a systematic review of palivizumab utilization.Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
P2860
Q24197915-AD0292A8-BB7E-44E9-97EA-20E49AB45B5EQ26864494-3AC4842A-4B73-4500-8A7A-7F432E3CDB39Q30245434-F499D132-485D-45E9-B220-DC7CE47ED74DQ33412776-BD34B4FB-E7BA-462A-8AFE-00912EA6E5A0Q34726089-DB99E01E-90D0-4FFC-A9E1-E0DE39858EE5Q36404178-38013DBA-DD73-480C-8BF4-689994035E6DQ37729137-930227CB-8D7A-43E9-95A7-4E45CD852110Q38079432-8CC146C9-D9A1-4F2A-9B40-7C0C56F97F7BQ38291356-FE1F70CD-0A0F-440F-BAC3-387AD761108FQ38604787-7F69A685-B3FC-4168-981F-D36EEB977987Q38628928-C3FE5B50-3E32-4AAA-9435-050446981198Q38671952-D55702D2-1CF3-4EF4-AF2A-84250799E4A8Q39205730-24098C61-4908-47EB-AA54-4F8FDD38DC55Q39362187-7971FCFB-45F7-4EF8-9517-191571D3445EQ39868227-4F5E25B9-A4D2-425E-9187-014FB2BE22DAQ47582466-6CEDAB73-DDB6-4BC4-ACD2-3021D86F3225Q57570436-AF53A051-717B-4163-AF77-80A789845348
P2860
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 2, randomized, double- ...... ministered in the same season.
@ast
A phase 2, randomized, double- ...... ministered in the same season.
@en
type
label
A phase 2, randomized, double- ...... ministered in the same season.
@ast
A phase 2, randomized, double- ...... ministered in the same season.
@en
prefLabel
A phase 2, randomized, double- ...... ministered in the same season.
@ast
A phase 2, randomized, double- ...... ministered in the same season.
@en
P2093
P2860
P356
P1433
P1476
A phase 2, randomized, double- ...... ministered in the same season.
@en
P2093
Adrian Trenholme
Brian Harris
Genevieve A Losonsky
Katia Abarca
M Pamela Griffin
Micki Hultquist
Motavizumab Study Group
Pilar Fernández
P2860
P2888
P356
10.1186/1471-2431-10-38
P577
2010-06-03T00:00:00Z
P5875
P6179
1018524453